Telehealth Platform Hims & Hers Enters Weight-Loss Drug Price War
Published on 04/02/2026 at 00:58 | Redaktion boerse-global.de
The competitive landscape for GLP-1 medications is shifting rapidly. Telehealth provider Hims & Hers has announced a strategic move, integrating Novo Nordisk's Wegovy into a new subscription model on its platform. This development coincides with rival Eli Lilly launching Foundayo, an additional oral weight-loss treatment, intensifying the battle for market share in this lucrative sector.
Financial Performance Remains Strong Amid Stock Decline
Despite recent stock market pressures, Hims & Hers continues to demonstrate robust operational health. The company reported full-year 2025 revenue of approximately $2.35 billion, representing a significant 59% increase over the prior year. Its subscriber base expanded to over 2.5 million users. For the fourth quarter of 2025, revenue rose 28% to $617.8 million. Annual net profit reached $128 million, while adjusted EBITDA more than doubled, climbing from $177 million to $318 million.
The company's equity performance, however, has not reflected this operational strength. Over the past six months, the share price has declined by roughly 63%. Current valuation models project a price target of $37 by December 2028. Based on a recent trading price near $21, this implies a potential upside of about 78%. These forecasts are grounded in expectations of sustained annual revenue growth of 15.6% and an operating margin of 6.7%.
Subscription Model Aims to Lower Patient Costs
Through its partnership with Novo Nordisk, Hims & Hers is now offering both Wegovy and Ozempic via a structured subscription plan. This model brings down monthly costs for consumers. Pricing for Wegovy injections is set between $249 and $329 per month, depending on the subscription term, which is notably below the previous standard price of $349. Oral versions are available for between $249 and $289 monthly.
Should investors sell immediately? Or is it worth buying Hims & Hers?
This pricing strategy positions the telehealth firm as a more affordable channel. The move is also seen as an effort to bolster Novo Nordisk, which currently holds an estimated 39% of the U.S. GLP-1 market, against leader Eli Lilly's dominant 60% share.
New Oral Competitor Increases Market Pressure
The competitive dynamics are further complicated by the recent regulatory approval of Eli Lilly's Foundayo. As the second oral GLP-1 drug following Novo Nordisk's pill version of Wegovy, Foundayo adds another option for patients. In its highest-dose Phase 3 trial, the treatment achieved an average weight reduction of 12.4% over a 72-week period.
Crucially, its pricing for self-pay patients ranges from $149 to $349 per month. At its most affordable tier, this makes Foundayo substantially cheaper than the Wegovy offerings available through the Hims & Hers platform. The arrival of such cost-effective oral alternatives will test the company's ability to maintain its margins while competing on price.
Hims & Hers at a turning point? This analysis reveals what investors need to know now.
The future trajectory for Hims & Hers will largely depend on how effectively it can defend its profitability in a market increasingly crowded with lower-priced options like Foundayo.
Ad
Hims & Hers Stock: New Analysis - 2 April
Fresh Hims & Hers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
